• Explore /
  • Poster
  • / Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).

Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).

Abstract Poster

Authors

null

B. Pro

Fox Chase Cancer Center, Philadelphia, PA

B. Pro , R. Advani , P. Brice , N. Bartlett , J. D. Rosenblatt , T. Illidge , J. Matous , R. Ramchandren , M. A. Fanale , J. M. Connors , Y. Yang , E. L. Sievers , D. A. Kennedy , A. R. Shustov

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2011 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lymphoma and Plasma Cell Disorders

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Lymphoma

Clinical Trial Registration Number

NCT00866047

Citation

J Clin Oncol 29: 2011 (suppl; abstr 8032)

Abstract #

8032

Poster Bd #

43D

Abstract Disclosures

Similar Posters

First Author: Paul M. Barr

First Author: Jie Xu

First Author: Lianna Jean Marks

First Author: Lorenzo Falchi